Dayton Business Journal—NuVasive Inc. is launching a set of spinal surgery products to address a $100 million market.The San Diego-based medical device manufacturer (Nasdaq: NUVA) announced a new product line, the Reline Trauma Portfolio, which will be a “minimally disruptive, procedurally-integrated” implant designed for easier and less invasive treatment of spinal traumas. Like all of the company’s spinal implant and medical device products, it will be manufactured at a $45 million center in West Carrollton.
“The system will be the foundation of our trauma portfolio as we invest further in this key market,” said Jason Hannon, president and chief operating officer of NuVasive in a statement.
The system makes it easier for surgeons to perform controlled, dial-in fracture correction, and is designed so it can be implanted by one physician instead of the typical two. It also allows for a more controlled method to correct a fracture with or without metal rods, meaning surgeons can reduce fractures more easily and preserve the fixes.
The company said it will help it tap into the spinal trauma fixation market, estimated a more than $100 million in the U.S. and growing 5.6 percent each year.
“The launch of Reline Trauma is a key milestone in our continued commitment to industry-leading innovation that delivers untapped clinical and economic value for our surgeon partners,” Hannon said. “Reline Trauma will help define the standard of trauma care for spine, with its ability to dramatically reduce time and provide complete versatility intra-operatively.”
The company is in the middle of setting up a $45 million manufacturing facilityin West Carrollton, which will be where all of its medical implants and other devices around the world are produced. By the end of this year it hopes to have 300 employees working there.
NuVasive, which saw $962 million in revenue last year, has 2,300 employees across the globe. It set a guidance for investors that 2017 revenue could grow another 11.4 percent to $1.1 billion.